US2802005A
(en)
|
|
1957-08-06 |
|
S-eluorourace |
US729332A
(en)
*
|
1902-07-21 |
1903-05-26 |
Frank C Guss |
Animal catching and holding device.
|
US2885396A
(en)
|
1957-03-21 |
1959-05-05 |
Heidelberger Charles |
N-glycosides of 5-fluorouracil
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
US3885035A
(en)
|
1972-04-05 |
1975-05-20 |
Sandoz Ag |
Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
|
CH605550A5
(ja)
|
1972-06-08 |
1978-09-29 |
Research Corp |
|
US3956495A
(en)
|
1973-10-30 |
1976-05-11 |
Eli Lilly And Company |
2,4-Diaminoquinazolines as antithrombotic agents
|
US3966936A
(en)
|
1974-02-21 |
1976-06-29 |
Pfizer Inc. |
Piperazino quinazoline bronchodilators
|
US4060615A
(en)
|
1976-02-18 |
1977-11-29 |
Mead Johnson & Company |
2-Piperazinyl-6,7-dimethoxyquinazolines
|
JPS6041077B2
(ja)
|
1976-09-06 |
1985-09-13 |
喜徳 喜谷 |
1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体
|
JPS562968A
(en)
|
1979-06-21 |
1981-01-13 |
Mitsubishi Yuka Yakuhin Kk |
Novel pyrimidine derivative
|
US5260291A
(en)
|
1981-08-24 |
1993-11-09 |
Cancer Research Campaign Technology Limited |
Tetrazine derivatives
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
EP0184365B1
(en)
|
1984-12-04 |
1993-08-04 |
Eli Lilly And Company |
Improvements in the treatment of tumors in mammals
|
JPS6270A
(ja)
|
1985-03-07 |
1987-01-06 |
Sankyo Co Ltd |
シクロペンタ〔d〕ピリミジン誘導体
|
US5583024A
(en)
|
1985-12-02 |
1996-12-10 |
The Regents Of The University Of California |
Recombinant expression of Coleoptera luciferase
|
EP0257102B1
(en)
|
1986-02-24 |
1997-11-19 |
Mitsui Petrochemical Industries, Ltd. |
Agents for treating neurophathy
|
FR2601675B1
(fr)
|
1986-07-17 |
1988-09-23 |
Rhone Poulenc Sante |
Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
|
US4889856A
(en)
|
1987-08-31 |
1989-12-26 |
Merck & Co., Inc. |
7,8-dihydro-4-(1-pierazinyl)-6H-thiopyrano-[3,2-d] pyrimidines as β-blockers
|
US4871739A
(en)
|
1987-01-21 |
1989-10-03 |
Merck & Co., Inc. |
Substituted 6H-7,8-dihydrothiapyrano(3,2-D)-pyrimidines as hyopglycemic agents
|
US4994464A
(en)
|
1987-08-31 |
1991-02-19 |
Merck & Co., Inc. |
Piperazinylpyrimidines as β-adrenergic receptor blockers
|
WO1990007926A1
(en)
|
1989-01-20 |
1990-07-26 |
Pfizer Inc. |
3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
|
US20030206899A1
(en)
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
WO1992022653A1
(en)
|
1991-06-14 |
1992-12-23 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5714512A
(en)
|
1991-07-08 |
1998-02-03 |
Rhone-Poulenc Rorer, S.A. |
Compositions containing taxane derivatives
|
US5698582A
(en)
|
1991-07-08 |
1997-12-16 |
Rhone-Poulenc Rorer S.A. |
Compositions containing taxane derivatives
|
US5750561A
(en)
|
1991-07-08 |
1998-05-12 |
Rhone-Poulenc Rorer, S.A. |
Compositions containing taxane derivatives
|
US5604213A
(en)
|
1992-03-31 |
1997-02-18 |
British Technology Group Limited |
17-substituted steroids useful in cancer treatment
|
DE69329067T2
(de)
|
1992-10-05 |
2001-05-10 |
Ube Industries, Ltd. |
Pyridmidin-derivate
|
DE69233803D1
(de)
|
1992-10-28 |
2011-03-31 |
Genentech Inc |
Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
|
FR2698543B1
(fr)
|
1992-12-02 |
1994-12-30 |
Rhone Poulenc Rorer Sa |
Nouvelles compositions à base de taxoides.
|
WO1995003286A1
(fr)
|
1993-07-23 |
1995-02-02 |
The Green Cross Corporation |
Derive de triazole et son utilisation pharmaceutique
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
GB9416189D0
(en)
|
1994-08-10 |
1994-09-28 |
Merck Sharp & Dohme |
Therapeutic agents
|
CA2197298C
(en)
|
1994-08-13 |
1999-10-19 |
Jong Wook Lee |
Novel pyrimidine derivatives and processes for the preparation thereof
|
US5543523A
(en)
|
1994-11-15 |
1996-08-06 |
Regents Of The University Of Minnesota |
Method and intermediates for the synthesis of korupensamines
|
US5525625A
(en)
|
1995-01-24 |
1996-06-11 |
Warner-Lambert Company |
2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
JPH08336393A
(ja)
|
1995-04-13 |
1996-12-24 |
Mitsubishi Chem Corp |
光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
|
US7067664B1
(en)
|
1995-06-06 |
2006-06-27 |
Pfizer Inc. |
Corticotropin releasing factor antagonists
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US7294332B2
(en)
|
1995-10-04 |
2007-11-13 |
Schering Corporation |
Combination therapy (temozolomide and α-IFN) for advanced cancer
|
ZA979961B
(en)
|
1996-11-15 |
1999-05-05 |
Lilly Co Eli |
5-HT1F agonists
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
DK0973804T3
(da)
|
1997-04-07 |
2007-05-07 |
Genentech Inc |
Anti-VEGF-antistoffer
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
DK1695985T3
(da)
|
1997-04-07 |
2011-06-14 |
Genentech Inc |
Fremgangsmåde til dannelse af humaniserede antistoffer ved tilfældig mutagenese
|
ES2274572T3
(es)
|
1997-07-01 |
2007-05-16 |
Warner-Lambert Company Llc |
Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek.
|
CN1163475C
(zh)
|
1997-07-01 |
2004-08-25 |
沃尼尔·朗伯公司 |
4-溴或4-碘苯基氨基苯氧肟酸衍生物及其作为mek抑制剂的用途
|
US6310060B1
(en)
|
1998-06-24 |
2001-10-30 |
Warner-Lambert Company |
2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
|
US6506798B1
(en)
|
1997-07-01 |
2003-01-14 |
Warner-Lambert Company |
4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
|
US6821963B2
(en)
|
1997-07-01 |
2004-11-23 |
Warner-Lambert Company |
4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
|
US6602677B1
(en)
|
1997-09-19 |
2003-08-05 |
Promega Corporation |
Thermostable luciferases and methods of production
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
DE69943144D1
(de)
|
1998-03-31 |
2011-03-03 |
Kyowa Hakko Kirin Co Ltd |
Stickstoffenthaltende heterocyclische verbindungen
|
DE19853278A1
(de)
|
1998-11-19 |
2000-05-25 |
Aventis Pharma Gmbh |
Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
JP2002534380A
(ja)
|
1999-01-07 |
2002-10-15 |
ワーナー−ランバート・カンパニー |
Mek阻害剤による喘息の治療
|
AU2203800A
(en)
|
1999-01-07 |
2000-07-24 |
Warner-Lambert Company |
Antiviral method using mek inhibitors
|
CA2348236A1
(en)
|
1999-01-13 |
2000-07-20 |
Stephen Douglas Barrett |
4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
|
EP1144385B1
(en)
|
1999-01-13 |
2005-08-17 |
Warner-Lambert Company Llc |
Benzoheterocycles and their use as mek inhibitors
|
CA2349832A1
(en)
|
1999-01-13 |
2000-07-20 |
Warner-Lambert Company |
Benzenesulfonamide derivatives and their use as mek inhibitors
|
US6455582B1
(en)
|
1999-01-13 |
2002-09-24 |
Warner-Lambert Company |
Sulohydroxamic acids and sulohyroxamates and their use as MEK inhibitors
|
OA11819A
(en)
|
1999-01-13 |
2005-08-17 |
Warner Lambert Co |
1-Heterocycle substituted diarylamines.
|
BR9916857A
(pt)
|
1999-01-13 |
2001-12-04 |
Warner Lambert Co |
4 heteroaril diarilaminas
|
US9534254B1
(en)
|
1999-02-02 |
2017-01-03 |
Abbott Molecular Inc. |
Patient stratification for cancer therapy based on genomic DNA microarray analysis
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
GB9910577D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
EP1192151B1
(en)
|
1999-07-09 |
2007-11-07 |
Glaxo Group Limited |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
AU5912500A
(en)
|
1999-07-16 |
2001-02-05 |
Warner-Lambert Company |
Method for treating chronic pain using mek inhibitors
|
KR20020012315A
(ko)
|
1999-07-16 |
2002-02-15 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
Mek 저해제를 사용한 만성 통증의 치료 방법
|
IL147617A0
(en)
|
1999-07-16 |
2002-08-14 |
Warner Lambert Co |
Method for treating chronic pain using mek inhibitors
|
WO2001005390A2
(en)
|
1999-07-16 |
2001-01-25 |
Warner-Lambert Company |
Method for treating chronic pain using mek inhibitors
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
MXPA02008103A
(es)
|
2000-03-15 |
2002-11-29 |
Warner Lambert Co |
Diarilaminas sustituidas con 5-amida como inhibidores mek.
|
KR100850393B1
(ko)
|
2000-06-30 |
2008-08-04 |
글락소 그룹 리미티드 |
퀴나졸린 화합물의 제조방법
|
ES2461854T3
(es)
|
2000-07-19 |
2014-05-21 |
Warner-Lambert Company Llc |
Ésteres oxigenados de ácidos 4-yodofenilamino-benzhidroxámicos
|
AU2001277044A1
(en)
|
2000-08-25 |
2002-03-13 |
Warner-Lambert Company Llc |
Process for making N-aryl-anthranilic acids and their derivatives
|
JP4105948B2
(ja)
|
2000-09-15 |
2008-06-25 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼインヒビターとして有用なピラゾール化合物
|
AU2002210714A1
(en)
|
2000-11-02 |
2002-06-11 |
Astrazeneca Ab |
Substituted quinolines as antitumor agents
|
WO2002056912A2
(en)
|
2001-01-16 |
2002-07-25 |
Glaxo Group Limited |
Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
|
WO2002083139A1
(en)
|
2001-04-10 |
2002-10-24 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
AR033295A1
(es)
|
2001-04-30 |
2003-12-10 |
Glaxo Group Ltd |
Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica
|
NZ518726A
(en)
|
2001-05-09 |
2004-06-25 |
Warner Lambert Co |
Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
|
WO2003022214A2
(en)
|
2001-09-06 |
2003-03-20 |
Millennium Pharmaceuticals, Inc. |
Piperazine and homopiperazine compounds
|
CA2468266A1
(en)
|
2001-12-06 |
2003-06-19 |
Merck & Co., Inc. |
Substituted bicyclic pyrimidinones as a mitotic kinesin ksp inhibitors
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
JP4469179B2
(ja)
|
2002-01-23 |
2010-05-26 |
バイエル ファーマセチカル コーポレーション |
Rhoキナーゼ阻害剤としてのピリミジン誘導体
|
TW200306819A
(en)
|
2002-01-25 |
2003-12-01 |
Vertex Pharma |
Indazole compounds useful as protein kinase inhibitors
|
SI2130537T1
(sl)
|
2002-03-13 |
2013-01-31 |
Array Biopharma, Inc. |
N3-alkilirani derivati benzimidazola kot inhibitorji mek
|
CN1652792A
(zh)
|
2002-03-13 |
2005-08-10 |
阵列生物制药公司 |
作为mek抑制剂的n3烷基化苯并咪唑衍生物
|
US7235537B2
(en)
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
CA2480880C
(en)
|
2002-04-08 |
2011-03-22 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
CA2480800C
(en)
|
2002-04-08 |
2008-09-23 |
Mark T. Bilodeau |
Inhibitors of akt activity
|
US20050182256A1
(en)
|
2002-04-08 |
2005-08-18 |
Duggan Mark E. |
Inhibitors of akt activity
|
AU2003226271B2
(en)
|
2002-04-08 |
2007-10-18 |
Merck Sharp & Dohme Corp. |
Fused quinoxaline derivatives as inhibitors of Akt activity
|
AU2003230367A1
(en)
|
2002-05-10 |
2003-11-11 |
Neurocrine Biosciences, Inc. |
Substituted piperazine as melanocortin receptors ligands
|
US20040102360A1
(en)
|
2002-10-30 |
2004-05-27 |
Barnett Stanley F. |
Combination therapy
|
EP1558586B1
(en)
|
2002-10-30 |
2011-03-30 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
MXPA05003431A
(es)
|
2002-11-15 |
2005-07-05 |
Warner Lambert Co |
Quimioterapia de combinacion.
|
EA200500721A1
(ru)
|
2002-11-28 |
2005-12-29 |
Шеринг Акциенгезельшафт |
Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
|
GB0308208D0
(en)
|
2003-04-09 |
2003-05-14 |
Glaxo Group Ltd |
Chemical compounds
|
US7638530B2
(en)
|
2003-04-24 |
2009-12-29 |
Merck & Co., Inc. |
Inhibitors of Akt activity
|
MXPA05012723A
(es)
|
2003-05-30 |
2006-02-08 |
Genentech Inc |
Tratamiento con anticuerpos anti-vgf.
|
DE602004022819D1
(de)
|
2003-06-06 |
2009-10-08 |
Vertex Pharma |
Von atp-bindende kassette transportern
|
AR045134A1
(es)
|
2003-07-29 |
2005-10-19 |
Smithkline Beecham Plc |
Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
TW200521119A
(en)
|
2003-08-05 |
2005-07-01 |
Vertex Pharma |
Compositions useful as inhibitors of voltage-gated ion channels
|
DE602004009200T2
(de)
|
2003-08-12 |
2008-07-10 |
F. Hoffmann-La Roche Ag |
Tetrahydrochinazolinderivate als cfr-antagonisten
|
AU2004272437A1
(en)
|
2003-09-09 |
2005-03-24 |
Ono Pharmaceutical Co., Ltd. |
CRF antagonists and heterobicyclic compounds
|
US20050182061A1
(en)
|
2003-10-02 |
2005-08-18 |
Jeremy Green |
Phthalimide compounds useful as protein kinase inhibitors
|
BRPI0415710A
(pt)
|
2003-10-21 |
2006-12-19 |
Warner Lambert Co |
formas polimórficas de n-[(r)-2,3-dihidróxi-propóxi]-3,4-diflúor-2-(2-flúor-4-io dofenilamino)-benzamida
|
NZ547327A
(en)
|
2003-11-21 |
2009-08-28 |
Array Biopharma Inc |
AKT protein kinase inhibitors
|
EP1696920B8
(en)
|
2003-12-19 |
2015-05-06 |
Plexxikon Inc. |
Compounds and methods for development of ret modulators
|
ES2629682T3
(es)
|
2004-03-29 |
2017-08-14 |
University Of South Florida |
Tratamiento efectivo de tumores y cáncer con fosfato de triciribina
|
CA2563699C
(en)
|
2004-04-23 |
2014-03-25 |
Exelixis, Inc. |
Kinase modulators and method of use
|
ATE464303T1
(de)
|
2004-04-28 |
2010-04-15 |
Vertex Pharma |
Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
|
US20060009360A1
(en)
|
2004-06-25 |
2006-01-12 |
Robert Pifer |
New adjuvant composition
|
WO2006000589A1
(en)
|
2004-06-28 |
2006-01-05 |
Altana Pharma Ag |
4,6-disubstituted pyrimidines and their use as protein kinase inhibitors
|
US20060025074A1
(en)
|
2004-07-30 |
2006-02-02 |
Chih-Ming Liang |
Bluetooth-based headset
|
TWM266655U
(en)
|
2004-09-23 |
2005-06-01 |
Blueexpert Technology Corp |
Bluetooth earphone device capable of wirelessly receiving and transmitting stereo sound signal and digital information signal
|
TW200621257A
(en)
|
2004-10-20 |
2006-07-01 |
Astellas Pharma Inc |
Pyrimidine derivative fused with nonaromatic ring
|
UY29177A1
(es)
|
2004-10-25 |
2006-05-31 |
Astex Therapeutics Ltd |
Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
|
JP5274842B2
(ja)
|
2004-12-28 |
2013-08-28 |
エグゼリクシス, インコーポレイテッド |
免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター(p70S6K、Akt−1およびAkt−2)としての[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジンまたは[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジン化合物
|
WO2006090261A1
(en)
|
2005-02-24 |
2006-08-31 |
Pfizer Products Inc. |
Bicyclic heteroaromatic derivatives useful as anticancer agents
|
EP1866822A4
(en)
|
2005-03-03 |
2010-09-01 |
Burnham Inst Medical Research |
ANALYSIS METHODS FOR DETECTION OF PROTEIN KINASE B INHIBITORS BASED ON VIRTUAL FIXATION APPROACHES, AND COMPOUNDS AND COMPOSITIONS DRAWN UP THEREFROM
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
EP2354140A1
(en)
|
2005-05-20 |
2011-08-10 |
Vertex Pharmaceuticals Incorporated |
Pyrrolopyridines useful as inhibitors of protein kinase
|
AR054485A1
(es)
|
2005-06-21 |
2007-06-27 |
Cancer Rec Tech Ltd |
ARIL-ALQUILAMINAS Y HETEROARIL-ALQUILAMINAS COMO INHIBIDORES DE PROTEINA QUINASA A Y B, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ORIGINADAS EN EL CRECIMIENTO ANORMAL DE LA
|
NZ565255A
(en)
*
|
2005-06-22 |
2010-04-30 |
Plexxikon Inc |
Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
|
EP1934174B1
(en)
|
2005-10-07 |
2011-04-06 |
Exelixis, Inc. |
Azetidines as mek inhibitors for the treatment of proliferative diseases
|
AU2006301435A1
(en)
|
2005-10-13 |
2007-04-19 |
Glaxo Group Limited |
Pyrrolopyrimidine derivatives as Syk inhibitors
|
US7960545B2
(en)
|
2005-11-23 |
2011-06-14 |
Natco Pharma Limited |
Process for the prepartion of erlotinib
|
AR056893A1
(es)
|
2005-12-28 |
2007-10-31 |
Takeda Pharmaceutical |
Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides
|
EP1990253B1
(en)
†
|
2006-03-02 |
2019-06-12 |
NSK Ltd. |
Torque sensor
|
WO2007125320A1
(en)
|
2006-04-25 |
2007-11-08 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
RU2008152171A
(ru)
|
2006-07-05 |
2010-08-10 |
Интермьюн, Инк. (Us) |
Новые ингибиторы вирусной репликации гепатита с
|
NZ573979A
(en)
|
2006-07-06 |
2012-02-24 |
Array Biopharma Inc |
Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
UA95641C2
(en)
*
|
2006-07-06 |
2011-08-25 |
Эррей Биофарма Инк. |
Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
GB0613518D0
(en)
|
2006-07-06 |
2006-08-16 |
Phytopharm Plc |
Chemical compounds
|
AU2007271182B2
(en)
|
2006-07-06 |
2012-03-15 |
Glaxo Group Limited |
Substituted N-phenylmethyl -5-oxo-proline-2-amides as P2X7-receptor antagonists and their methods of use
|
TW200808325A
(en)
|
2006-07-06 |
2008-02-16 |
Astrazeneca Ab |
Novel compounds
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
WO2008006039A1
(en)
|
2006-07-06 |
2008-01-10 |
Array Biopharma Inc. |
Dihydrothieno pyrimidines as akt protein kinase inhibitors
|
US7910747B2
(en)
|
2006-07-06 |
2011-03-22 |
Bristol-Myers Squibb Company |
Phosphonate and phosphinate pyrazolylamide glucokinase activators
|
WO2008012635A2
(en)
|
2006-07-26 |
2008-01-31 |
Pfizer Products Inc. |
Amine derivatives useful as anticancer agents
|
PE20080538A1
(es)
|
2006-08-04 |
2008-06-18 |
Takeda Pharmaceutical |
Derivado heterociclico fusionado y su uso
|
PL2061561T3
(pl)
*
|
2006-08-25 |
2013-12-31 |
Janssen Oncology Inc |
Kompozycje do leczenia raka
|
US8828451B2
(en)
|
2006-10-04 |
2014-09-09 |
University Of South Florida |
Akt sensitization of cancer cells
|
CN101332301A
(zh)
*
|
2007-06-26 |
2008-12-31 |
南京医科大学 |
一种抗肿瘤组合物及其应用
|
KR101618037B1
(ko)
|
2007-07-12 |
2016-05-04 |
유니버시티 오브 사우스 플로리다 |
항종양 활성이 있는 Akt/PKB 저해제
|
EP2170062A4
(en)
|
2007-07-12 |
2010-12-29 |
Tragara Pharmaceuticals Inc |
METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
|
US8137919B2
(en)
|
2008-04-10 |
2012-03-20 |
Montefiore Medical Center |
Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
|
JP5579715B2
(ja)
*
|
2008-07-29 |
2014-08-27 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ
|
WO2010014939A1
(en)
|
2008-07-31 |
2010-02-04 |
Genentech, Inc. |
Pyrimidine compounds, compositions and methods of use
|
SG194045A1
(en)
|
2011-04-01 |
2013-11-29 |
Genentech Inc |
Combinations of akt inhibitor compounds and abiraterone, and methods of use
|
EP2694959B8
(en)
*
|
2011-04-01 |
2019-12-25 |
Genentech, Inc. |
Biomarkers for predicting sensitivity to cancer treatments
|